BCRX, US09058V1035

BioCryst stock: ORLADEYO data show fewer HAE-related visits

Published on 11/17/2026 at 22:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
BioCryst stock is tied to new ORLADEYO evidence in hereditary angioedema. Switching patients recorded 30 percent fewer related visits per patient-year.

ORLADEYO study results

  • Patients switching to ORLADEYO recorded 30 percent fewer angioedema-related visits per patient-year.
  • A separate study found a 53 percent reduction in all-cause hospitalizations among treatment-naive patients starting ORLADEYO.
  • BioCryst will present at the Jefferies Global Healthcare Conference on November 18, 2026.
BCRX, US09058V1035, Illustration mit AI erstellt.

BioCryst Pharmaceuticals presented new real-world evidence on November 13, 2026, showing fewer healthcare visits among hereditary angioedema patients using ORLADEYO. The company said the findings were presented at the American College of Allergy, Asthma & Immunology annual meeting in Phoenix.

In a retrospective study of 78 patients aged 12 and older who switched from another long-term prophylactic therapy to ORLADEYO, angioedema-related visits fell 30 percent per patient-year. Outpatient and emergency department visits also declined 30 percent per patient-year. Angioedema-related hospitalizations fell to 0.12 per patient-year after the switch, but that reduction was not statistically significant.

A second study examined treatment-naive patients who began ORLADEYO, lanadelumab or subcutaneous plasma-derived C1-inhibitor. The ORLADEYO group recorded a 53 percent reduction in all-cause hospitalizations and a 61 percent reduction in angioedema-related emergency department visits. BioCryst said the size of the reductions did not differ significantly between the treatment groups.

The company described the findings in a BioCryst press release. The results support the commercial positioning of ORLADEYO, while the company continues to develop navenibart as an investigational therapy for long-term hereditary angioedema prevention.

BioCryst stock traded at 6.82 euros on Lang & Schwarz at 22:04 CET on Tuesday, November 17, 2026.

BioCryst Pharmaceuticals

  • Company: BioCryst Pharmaceuticals, Inc.
  • ISIN: US09058V1035
  • Nasdaq ticker: BCRX
  • Lang & Schwarz price: 6.82 euros at 22:04 CET on November 17, 2026

The broader market setting is available through the Nasdaq Composite theme.

More news and analyses on BioCryst Pharmaceuticals stock.

Disclaimer...
en | US09058V1035 | BCRX | boerse | 70528687 | bgmi